Details of the Drug

General Information of Drug (ID: DM17ONX)

Drug Name

Fexofenadine

Synonyms

Carboxyterfenadine; Fexofendine; Terfenadine acid metabolite; Terfenadine carboxylate; F 9427; MDL 16455; Allegra (TN); Fastofen (TN); Fexofenadine (INN); Fexofenadine [INN:BAN]; Telfast (TN); Terfenadine-COOH; Terfenidine carboxylate, MDL 16455; Tilfur (TN); 2-[4-(1-hydroxy-4-{4-[hydroxy(diphenyl)methyl]piperidin-1-yl}butyl)phenyl]-2-methylpropanoic acid; 2-[4-[1-hydroxy-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butyl]phenyl]-2-methylpropanoic acid; 4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)-1-piperidinyl)butyl)-alpha,alpha-dimethylbenzeneacetic acid

Indication

Disease Entry	ICD 11	Status	REF
Allergic rhinitis	CA08.0	Approved	[1]
Seasonal allergic rhinitis	CA08.01	Approved	[2]
------------------------------------------------------------------------------------

Therapeutic Class

Antiallergic Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 1

Molecular Weight (mw)

501.7

Logarithm of the Partition Coefficient (xlogp)

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 1367 mcgh/L [3]
Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 299 mcg/L [3]
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 1-3 h [3]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [4]
Bioavailability: The bioavailability of drug is 33% [3]
Clearance: The renal clearance of drug is 4.32 L/h [3]
Elimination: Approximately 80% of an ingested dose is eliminated in the feces, likely largely unchanged due to fexofenadine's limited metabolism, and 11% is eliminated in the urine [5]
Half-life: The concentration or amount of drug in body reduced by one-half in 11 - 15 hours [3]
Metabolism: The drug is metabolized via the hepatic [3]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 5.1257 micromolar/kg/day [6]
Vd: The volume of distribution (Vd) of drug is 5.4-5.8 L/kg [5]

Chemical Identifiers

Formula: C32H39NO4
IUPAC Name: 2-[4-[1-hydroxy-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butyl]phenyl]-2-methylpropanoic acid
Canonical SMILES: CC(C)(C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O)C(=O)O
InChI: InChI=1S/C32H39NO4/c1-31(2,30(35)36)25-17-15-24(16-18-25)29(34)14-9-21-33-22-19-28(20-23-33)32(37,26-10-5-3-6-11-26)27-12-7-4-8-13-27/h3-8,10-13,15-18,28-29,34,37H,9,14,19-23H2,1-2H3,(H,35,36)
InChIKey: RWTNPBWLLIMQHL-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 3348
ChEBI ID: CHEBI:5050
CAS Number: 83799-24-0
DrugBank ID: DB00950
TTD ID: D01KPV
VARIDT ID: DR00026
ACDINA ID: D00273

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Histamine H1 receptor (H1R)	TTTIBOJ	HRH1_HUMAN	Antagonist	[7]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Multidrug resistance-associated protein 3 (ABCC3)	DTQ3ZHF	MRP3_HUMAN	Substrate	[8]
Organic cation transporter 1 (SLC22A1)	DTT79CX	S22A1_HUMAN	Substrate	[9]
Organic anion transporting polypeptide 2B1 (SLCO2B1)	DTPFTEQ	SO2B1_HUMAN	Substrate	[10]
Organic anion transporting polypeptide 1A2 (SLCO1A2)	DTE2B1D	SO1A2_HUMAN	Substrate	[11]
Organic anion transporting polypeptide 1B3 (SLCO1B3)	DT9C1TS	SO1B3_HUMAN	Substrate	[12]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[13]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Antileukoproteinase (SLPI)	OTUNFUU8	SLPI_HUMAN	Gene/Protein Processing	[14]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Drug Response	[15]
C-C motif chemokine 17 (CCL17)	OTIKW21L	CCL17_HUMAN	Gene/Protein Processing	[16]
C-C motif chemokine 22 (CCL22)	OTT3QJC2	CCL22_HUMAN	Gene/Protein Processing	[16]
Cystine/glutamate transporter (SLC7A11)	OTKJ6PXW	XCT_HUMAN	Gene/Protein Processing	[14]
Hepatocyte growth factor receptor (MET)	OT7K55MU	MET_HUMAN	Gene/Protein Processing	[14]
Intercellular adhesion molecule 1 (ICAM1)	OTTOIX77	ICAM1_HUMAN	Gene/Protein Processing	[17]
Interleukin-1 alpha (IL1A)	OTPSGILV	IL1A_HUMAN	Gene/Protein Processing	[14]
Interleukin-1 beta (IL1B)	OT0DWXXB	IL1B_HUMAN	Gene/Protein Processing	[14]
Interleukin-8 (CXCL8)	OTS7T5VH	IL8_HUMAN	Gene/Protein Processing	[14]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Allergic rhinitis

ICD Disease Classification

CA08.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Histamine H1 receptor (H1R)	DTT	HRH1	6.74E-01	0.13	0.43
P-glycoprotein 1 (ABCB1)	DTP	P-GP	6.54E-01	1.95E-01	4.04E-01
Organic cation transporter 1 (SLC22A1)	DTP	SLC22A1	6.27E-01	5.04E-02	1.96E-01
Multidrug resistance-associated protein 3 (ABCC3)	DTP	MRP3	9.17E-01	-6.21E-03	-3.18E-02
Organic anion transporting polypeptide 2B1 (SLCO2B1)	DTP	OATP2B1	7.68E-01	-7.76E-02	-1.74E-01
Organic anion transporting polypeptide 1A2 (SLCO1A2)	DTP	OATP1A2	7.98E-01	1.52E-01	2.97E-01
Organic anion transporting polypeptide 1B3 (SLCO1B3)	DTP	OATP1B3	8.56E-01	3.16E-02	2.99E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Fexofenadine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Midostaurin	DMI6E0R	Moderate	Decreased clearance of Fexofenadine due to the transporter inhibition by Midostaurin.	Acute myeloid leukaemia [2A60]	[18]
Arn-509	DMT81LZ	Moderate	Accelerated clearance of Fexofenadine due to the transporter induction by Arn-509.	Acute myeloid leukaemia [2A60]	[18]
Gilteritinib	DMTI0ZO	Moderate	Decreased clearance of Fexofenadine due to the transporter inhibition by Gilteritinib.	Acute myeloid leukaemia [2A60]	[19]
Dronedarone	DMA8FS5	Moderate	Decreased clearance of Fexofenadine due to the transporter inhibition by Dronedarone.	Angina pectoris [BA40]	[20]
Clarithromycin	DM4M1SG	Minor	Decreased clearance of Fexofenadine due to the transporter inhibition by Clarithromycin.	Bacterial infection [1A00-1C4Z]	[21]
Troleandomycin	DMUZNIG	Minor	Decreased clearance of Fexofenadine due to the transporter inhibition by Troleandomycin.	Bacterial infection [1A00-1C4Z]	[21]
Ag-221	DMS0ZBI	Moderate	Decreased clearance of Fexofenadine due to the transporter inhibition by Ag-221.	BCR-ABL1-negative chronic myeloid leukaemia [2A41]	[19]
Erdafitinib	DMI782S	Moderate	Decreased clearance of Fexofenadine due to the transporter inhibition by Erdafitinib.	Bladder cancer [2C94]	[22]
Tucatinib	DMBESUA	Moderate	Decreased clearance of Fexofenadine due to the transporter inhibition by Tucatinib.	Breast cancer [2C60-2C6Y]	[23]
PF-04449913	DMSB068	Moderate	Decreased clearance of Fexofenadine due to the transporter inhibition by PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[18]
Ivacaftor	DMZC1HS	Moderate	Decreased clearance of Fexofenadine due to the transporter inhibition by Ivacaftor.	Cystic fibrosis [CA25]	[24]
MK-8228	DMOB58Q	Moderate	Decreased clearance of Fexofenadine due to the transporter inhibition by MK-8228.	Cytomegaloviral disease [1D82]	[25]
Itraconazole	DMCR1MV	Minor	Decreased clearance of Fexofenadine due to the transporter inhibition by Itraconazole.	Fungal infection [1F29-1F2F]	[21]
Miconazole	DMPMYE8	Minor	Decreased clearance of Fexofenadine due to the transporter inhibition by Miconazole.	Fungal infection [1F29-1F2F]	[21]
Ketoconazole	DMPZI3Q	Minor	Decreased clearance of Fexofenadine due to the transporter inhibition by Ketoconazole.	Fungal infection [1F29-1F2F]	[21]
GS-5885	DMSL3DX	Moderate	Decreased clearance of Fexofenadine due to the transporter inhibition by GS-5885.	Hepatitis virus infection [1E50-1E51]	[26]
Rifampin	DMA8J1G	Moderate	Accelerated clearance of Fexofenadine due to the transporter induction by Rifampin.	HIV-infected patients with tuberculosis [1B10-1B14]	[27]
Fostemsavir	DM50ILT	Moderate	Decreased clearance of Fexofenadine due to the transporter inhibition by Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[28]
Bempedoic acid	DM1CI9R	Moderate	Decreased clearance of Fexofenadine due to the transporter inhibition by Bempedoic acid.	Hyper-lipoproteinaemia [5C80]	[29]
BMS-201038	DMQTAGO	Moderate	Decreased clearance of Fexofenadine due to the transporter inhibition by BMS-201038.	Hyper-lipoproteinaemia [5C80]	[30]
Tolvaptan	DMIWFRL	Moderate	Decreased clearance of Fexofenadine due to the transporter inhibition by Tolvaptan.	Hypo-osmolality/hyponatraemia [5C72]	[19]
Capmatinib	DMYCXKL	Moderate	Decreased clearance of Fexofenadine due to the transporter inhibition by Capmatinib.	Lung cancer [2C25]	[31]
Ibrutinib	DMHZCPO	Moderate	Decreased clearance of Fexofenadine due to the transporter inhibition by Ibrutinib.	Mature B-cell lymphoma [2A85]	[18]
Lasmiditan	DMXLVDT	Moderate	Decreased clearance of Fexofenadine due to the transporter inhibition by Lasmiditan.	Migraine [8A80]	[32]
Nilotinib	DM7HXWT	Moderate	Decreased clearance of Fexofenadine due to the transporter inhibition by Nilotinib.	Myeloproliferative neoplasm [2A20]	[33]
Rolapitant	DM8XP26	Moderate	Decreased clearance of Fexofenadine due to the transporter inhibition by Rolapitant.	Nausea/vomiting [MD90]	[34]
Lonafarnib	DMGM2Z6	Moderate	Decreased clearance of Fexofenadine due to the transporter inhibition by Lonafarnib.	Premature ageing appearance [LD2B]	[35]
Enzalutamide	DMGL19D	Moderate	Accelerated clearance of Fexofenadine due to the transporter induction by Enzalutamide.	Prostate cancer [2C82]	[36]
Darolutamide	DMV7YFT	Moderate	Decreased clearance of Fexofenadine due to the transporter inhibition by Darolutamide.	Prostate cancer [2C82]	[18]
Fostamatinib	DM6AUHV	Moderate	Decreased clearance of Fexofenadine due to the transporter inhibition by Fostamatinib.	Thrombocytopenia [3B64]	[37]
Eltrombopag	DMOGFIX	Moderate	Decreased clearance of Fexofenadine due to the transporter inhibition by Eltrombopag.	Thrombocytopenia [3B64]	[38]
-----------


⏷ Show the Full List of 31 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
Aspartame	E00402	134601	Flavoring agent
D&C red no. 28	E00491	6097185	Colorant
D&C red no. 33	E00261	19116	Colorant
FD&C blue no. 1	E00263	19700	Colorant
Kyselina citronova	E00014	311	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Butylhydroxyanisole	E00308	24667	Antimicrobial preservative; Antioxidant
Carmellose sodium	E00625	Not Available	Disintegrant
Crospovidone	E00626	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferric oxide black	E00522	16211978	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Ferrous oxide	E00241	14945	Colorant
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000	E00654	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000	E00655	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium bicarbonate	E00424	516892	Alkalizing agent; Diluent
Sodium chloride	E00077	5234	Diluent; Tonicity agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Colcothar yellow	E00436	518696	Colorant
Haematite red	E00236	14833	Colorant
Hydrophobic colloidal silica	E00285	24261	Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
Cellulose microcrystalline	E00698	Not Available	Adsorbent; Suspending agent; Diluent
Pregelatinized starch	E00674	Not Available	Binding agent; Diluent; Disintegrant
--------------------


⏷ Show the Full List of 38 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Fexofenadine 30 mg tablet	30 mg	Oral Tablet	Oral
Fexofenadine 30 mg tablet	30 mg	Disintegrating Oral Tablet	Oral
Fexofenadine Hydrochloride 180mg tablet	180mg	Tablet	Oral
Fexofenadine Hydrochloride 60mg tablet	60mg	Tablet	Oral
Fexofenadine 180 mg tablet	180 mg	Oral Tablet	Oral
Fexofenadine 60 mg tablet	60 mg	Oral Tablet	Oral
Fexofenadine 180 mg tablet	180 mg	24 HR Extended Release Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4819).
2	Fexofenadine FDA Label
3	DPD Approved Drugs: Allegra? oral tablets
4	BDDCS applied to over 900 drugs
5	Devillier P, Roche N, Faisy C: Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review. Clin Pharmacokinet. 2008;47(4):217-30.
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	Update on prescription and over-the-counter histamine inverse agonists in rhinitis therapy. Curr Allergy Asthma Rep. 2009 Mar;9(2):140-8.
8	Involvement of multiple efflux transporters in hepatic disposition of fexofenadine. Mol Pharmacol. 2008 May;73(5):1474-83.
9	Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther. 2007 Mar;81(3):362-70.
10	The effects of the SLCO2B1 c.1457C>T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans. Pharmacogenet Genomics. 2011 Feb;21(2):84-93.
11	Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochem Pharmacol. 2010 Dec 1;80(11):1746-53.
12	Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans. Drug Metab Dispos. 2005 Oct;33(10):1477-81.
13	Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. Clin Pharmacol Ther. 2005 Aug;78(2):191-201.
14	An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
15	A variant 2677A allele of the MDR1 gene affects fexofenadine disposition. Clin Pharmacol Ther. 2004 Nov;76(5):418-27. doi: 10.1016/j.clpt.2004.08.002.
16	Effect of histamine H1 receptor antagonists on TARC/CCL17 and MDC/CCL22 production from CD14+ cells induced by antigenic stimulation in vitro. Int Arch Allergy Immunol. 2011;155(1):38-51. doi: 10.1159/000318720. Epub 2010 Nov 25.
17	The effect of fexofenadine on expression of intercellular adhesion molecule 1 and induction of apoptosis on peripheral eosinophils. Allergy Asthma Proc. 2005 Jul-Aug;26(4):292-8.
18	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
19	Cerner Multum, Inc. "Australian Product Information.".
20	Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
21	Product Information. Allegra (fexofenadine). Hoechst Marion-Roussel Inc, Kansas City, MO.
22	Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
23	Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
24	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
25	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
26	Product Information. Harvoni (ledipasvir-sofosbuvir). Gilead Sciences, Foster City, CA.
27	Bailey DG, Dresser GK, Munoz C, Freemar DJ, Kim RB "Reduction of fexofenadine bioavailability by fruit juices." Clin Pharmacol Ther 69 (2001): PI-82. [PMID: 15735611]
28	Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
29	Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
30	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
31	Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
32	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
33	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
34	Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
35	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
36	Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
37	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
38	Allred AJ, Bowen CJ, Park JW, et al. "Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers." Br J Clin Pharmacol 72 (2011): 321-9. [PMID: 21434975]